Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice - Tanaka, Takaaki; Hiraoka, Atsushi; Tada, Toshifumi; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Fukunishi, Shinya; Tsuji, Kunihiko; Ishikawa, Toru; et al. (Hepatology research, 2022)
Keywords: atezolizumab plus bevacizumab; Bevacizumab; Bilirubin; Child‐Pugh class B; Disease control; Hepatocellular carcinoma; Liver; Medical prognosis; modified albumin‐bilirubin grade; Patients; Prognosis; Survival; Child-Pugh class B; modified albumin-bilirubin grade; atezolizumab plus bevacizumab; prognosis; hepatocellular carcinoma